Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment (INTEREST)

12 de noviembre de 2026 actualizado por: University Hospital, Brest

Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.

Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.

This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Descripción detallada

Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.

Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.

The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.

The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.

The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

50

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Angers, Francia, 49000
      • Brest, Francia, 29200
      • Morlaix, Francia, 29600
        • Ch Pays de Morlaix
        • Contacto:
          • Christophe NICOL, Dr
          • Número de teléfono: 02 98 62 60 38
          • Correo electrónico: Cnicol@ch-morlaix.fr
      • Paris, Francia, 75475
      • Tours, Francia, 37044
        • Chu Tours
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
  • Stable cytoreductive therapy for at least 6 months
  • Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
  • Adult patient capable of providing informed consent

Exclusion Criteria:

  • Recurrent or poorly controlled infections
  • Thrombocytopenia < 100 G/L
  • Neutropenia < 1 G/L
  • Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
  • Concomitant immunosuppressive therapy
  • Refusal to participate
  • Patient under legal protection (guardianship, curatorship, etc.)
  • Patients unable to consent.
  • Positive urine pregnancy test at screening / pregnant or breastfeeding women.
  • Lack of understanding of questionnaires or inability to follow up.
  • Women of childbearing potential unwilling to use a highly effective contraceptive methods

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Anakinra + cytoreductive therapy

Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.

Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary.

Sin intervención: Cytoreductive therapy alone

Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in serum calprotectin levels
Periodo de tiempo: Baseline and Month 3

Calprotectin levels are measured on serum samples by centralized analysis (µg/mL)

Baseline and Month 3

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Improvement (yes/no) of the response status between baseline and month 3.
Periodo de tiempo: Month 3

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 3
Improvement (yes/no) of the response status between baseline and month 6.
Periodo de tiempo: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Improvement (yes/no) of the response status between month 3 and month 6.
Periodo de tiempo: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Hemoglobin count
Periodo de tiempo: Baseline

Measurement of Hemoglobin in g/dL

Baseline
Hematocrit count
Periodo de tiempo: Baseline

Measurement of Hematocrit in %

Baseline
White blood cell count
Periodo de tiempo: Baseline

Measurement of WBC in G/L

Baseline
Platelet cell count
Periodo de tiempo: Baseline

Measurement of Platelets in G/L

Baseline
Hemoglobin count
Periodo de tiempo: Month 3

Measurement of Hemoglobin in g/dL

Month 3
Hematocrit count
Periodo de tiempo: Month 3

Measurement of Hematocrit in %

Month 3
White blood cell count
Periodo de tiempo: Month 3

Measurement of WBC in G/L

Month 3
Platelet cell count
Periodo de tiempo: Month 3

Measurement of Platelets in G/L

Month 3
Hemoglobin count
Periodo de tiempo: Month 6

Measurement of Hemoglobin in g/dL

Month 6
Hematocrit count
Periodo de tiempo: Month 6

Measurement of Hematocrit in %

Month 6
White blood cell count
Periodo de tiempo: Month 6

Measurement of WBC in G/L

Month 6
Platelet cell count
Periodo de tiempo: Month 6

Measurement of Platelets in G/L

Month 6
Treatment-related adverse event for experimental group
Periodo de tiempo: Month 1

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 1
Treatment-related adverse event for experimental group
Periodo de tiempo: Month 3

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 3
Treatment-related adverse event for experimental group
Periodo de tiempo: Month 6

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 6
Adherence to treatment regimen for experimental group
Periodo de tiempo: Month 1

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation.

Month 1
Adherence to treatment regimen for experimental group
Periodo de tiempo: Month 2

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation

Month 2
Adherence to treatment regimen for experimental group
Periodo de tiempo: Month 3

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation.

Month 3
QLQ-C30 Summary Score
Periodo de tiempo: Baseline

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Baseline
QLQ-C30 Summary Score
Periodo de tiempo: Month 3

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 3
QLQ-C30 Summary Score
Periodo de tiempo: Month 6

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 6
Global health status / QoL score
Periodo de tiempo: Baseline

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Baseline
Global health status / QoL score
Periodo de tiempo: Month 3

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 3
Global health status / QoL score
Periodo de tiempo: Month 6

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 6
Patient-reported symptom severity over the previous 4 weeks for pruritus
Periodo de tiempo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever
Periodo de tiempo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Periodo de tiempo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for pruritus
Periodo de tiempo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever
Periodo de tiempo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Periodo de tiempo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for pruritus
Periodo de tiempo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever
Periodo de tiempo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Periodo de tiempo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Inflammatory biological profile
Periodo de tiempo: Baseline

Measurement of IL-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Periodo de tiempo: Month 3

Measurement of IL-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Periodo de tiempo: Month 6

Measurement of IL-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Periodo de tiempo: Baseline

Measurement of IL-6 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Periodo de tiempo: Month 3

Measurement of IL-6 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Periodo de tiempo: Month 6

Measurement of IL-6 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Periodo de tiempo: Baseline

Measurement of IL-8 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Periodo de tiempo: Month 3

Measurement of IL-8 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Periodo de tiempo: Month 6

Measurement of IL-8 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Periodo de tiempo: Baseline

Measurement of MIP-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Periodo de tiempo: Month 3

Measurement of MIP-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Periodo de tiempo: Month 6

Measurement of MIP-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Periodo de tiempo: Baseline

Measurement of TNF-α cytokines in pg/mL.

Baseline
Inflammatory biological profile
Periodo de tiempo: Month 3

Measurement of TNF-α cytokines in pg/mL.

Month 3
Inflammatory biological profile
Periodo de tiempo: Month 6

Measurement of TNF-α cytokines in pg/mL.

Month 6
Allele burden of the driver mutation
Periodo de tiempo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Baseline
Allele burden of the driver mutation
Periodo de tiempo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 3
Allele burden of the driver mutation
Periodo de tiempo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 6
Allele burden of the driver mutation
Periodo de tiempo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Baseline
Allele burden of the driver mutation
Periodo de tiempo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 3
Allele burden of the driver mutation
Periodo de tiempo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 6
Allele burden of the driver mutation
Periodo de tiempo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Baseline
Allele burden of the driver mutation
Periodo de tiempo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 3
Allele burden of the driver mutation
Periodo de tiempo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 6
Fibrosis markers
Periodo de tiempo: Baseline

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Baseline
Fibrosis markers
Periodo de tiempo: Month 3

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 3
Fibrosis markers
Periodo de tiempo: Month 6

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 6

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de febrero de 2027

Finalización primaria (Estimado)

1 de agosto de 2028

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

3 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir